NITE vs. PRME, PLX, IKT, IZTC, JATT, CVM, CRTX, ZIVO, ALVR, and FNCH
Should you be buying Nightstar Therapeutics stock or one of its competitors? The main competitors of Nightstar Therapeutics include Prime Medicine (PRME), Protalix BioTherapeutics (PLX), Inhibikase Therapeutics (IKT), Invizyne Technologies (IZTC), JATT Acquisition (JATT), CEL-SCI (CVM), Cortexyme (CRTX), ZIVO Bioscience (ZIVO), AlloVir (ALVR), and Finch Therapeutics Group (FNCH). These companies are all part of the "medical" sector.
Nightstar Therapeutics vs. Its Competitors
Nightstar Therapeutics (NASDAQ:NITE) and Prime Medicine (NYSE:PRME) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, dividends, institutional ownership, profitability, valuation, analyst recommendations, media sentiment and risk.
32.8% of Nightstar Therapeutics shares are held by institutional investors. Comparatively, 70.4% of Prime Medicine shares are held by institutional investors. 22.7% of Prime Medicine shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
In the previous week, Prime Medicine had 3 more articles in the media than Nightstar Therapeutics. MarketBeat recorded 3 mentions for Prime Medicine and 0 mentions for Nightstar Therapeutics. Prime Medicine's average media sentiment score of 0.63 beat Nightstar Therapeutics' score of 0.00 indicating that Prime Medicine is being referred to more favorably in the news media.
Nightstar Therapeutics has higher earnings, but lower revenue than Prime Medicine. Nightstar Therapeutics is trading at a lower price-to-earnings ratio than Prime Medicine, indicating that it is currently the more affordable of the two stocks.
Prime Medicine has a consensus price target of $8.92, suggesting a potential upside of 56.98%. Given Prime Medicine's stronger consensus rating and higher probable upside, analysts clearly believe Prime Medicine is more favorable than Nightstar Therapeutics.
Nightstar Therapeutics' return on equity of -30.89% beat Prime Medicine's return on equity.
Nightstar Therapeutics has a beta of 2.84, meaning that its share price is 184% more volatile than the S&P 500. Comparatively, Prime Medicine has a beta of 2.65, meaning that its share price is 165% more volatile than the S&P 500.
Summary
Prime Medicine beats Nightstar Therapeutics on 10 of the 15 factors compared between the two stocks.
Get Nightstar Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for NITE and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding NITE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Nightstar Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:NITE) was last updated on 10/10/2025 by MarketBeat.com Staff
